A 1.	1	-		
Form PTO-1449 (Modified)	OIPA	Atty. Docket No. 76891	9/385834	
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION	DEC 17 1999 C	JEFFREY L.C. WRIGHT		
DISCLOSURE STATEMENT (Use several sheets if necessary)	UEU / 1999 C	AUGUST 30, 1999	1761/6	#5
	( DIVINGA QE)			5
REFERENCE	DESIGNATION	U.S. PATENT DOCUME	ENTS	
EXAM.			SUB	FIL DATE IF

06/04/99

8

Ď

INIT.

8

0

REFERENCE DESIGNATION					ESIG	NATION	U.S. PATENT DOCUMENTS				
DO	CLIMI	א דוא?	IUMB:	ED		DATE	NAME	CLASS	SUB CLASS	FIL.DATE IF	
טט	COM	2141 17	OIVID.	CK		DATE	NAME	CLASS	CLASS	APPROPRIATE	
5	0	2	0	4	5	26/03/96	MIETTINEN ET AL.	514	182		

552

554

HIGGINS, III

FOREIGN PATENT DOCUMENTS															
				_						T			SUB	TRANS	LATION
				D	COM	ENT	NUME	BER		DATE	COUNTRY	CLASS	CLASS	YES	NO
	7	B1	wo	92	1	9	6	4	0	12/11/92	PCT				
	11	B2	wo	96	1	0	0	3	3	04/O4/96	PCT	~			
	11	В3	EP	0	594	612	В1			03/05/91	Europe				
	71	B4	wo	97	3	5	5	9	4	02/10/97	PCT			-	- CC
		B5 ·	WO	98	0	6	7	1	4	19/02/98	PCT		700 %	斯621	FOEI
m	П	B6	wo	98	1	8	4	2	9	07/05/98	PCT	_	A II		Fin
SOL	П	В7	EP	97	0	3	3	2	9	13/02/97	EUROPE			- 17.3	U
	П	B8	wo	99	3	0	5	6	9	24/06/99	PCT	_		5	
	П	B9	wo	98	0	1	7	5	9	15/01/98	PCT	_			
	V	B10	1	3	3	7	5	4	8	14/11/95	CA				

OTHER ART (including Author, Title, Date, Pertinent Pages, Etc.)

Criqui M.H., "Triglycerides and Cardiovascular Disease, A Focus on Clinical Trials", European Heart Journal 19 (Supplement A); A36-A39. Grundy, Scott M., "Small LDL, Atherogenic Dyslipidemia, and the Metabolic Syndrome", Circulation 95:1-4 (1997) C3 Grundy, Scott M., "Hypertriglyceridemia, Atherogenic Dyslipidemia, and the Metabolic Syndrome", American Journal of Cardiology, 81(4A):18B-25B (1998)ζŌν Gotto, Antonio M., Jr., "Triglyceride, The Forgotten Risk Factor", Circulation, 97:1027-1028 (1998) 4 Jeppesen, Jorgen, et al., "Triglyceride Concentration and Ischemic Heart Disease, An Eight-Year Follow-up in the Copenhagen Male Study", Circulation 97:1029-1036 (1998) Guido Franceschini and Rodolfo Paoletti, "Pharmacological Control of Hypertriglyceridemia", Cardiovascular Drugs and Therapy, 1993:7:297-302 (1993) •Eisenberg, Daniel, "The Importance of Lowering Cholesterol in Patients with Coronary Heart Disease", Clin. Cardiol. 21:81-84 (1998) C8 "Randomised Trial of Cholesterol Lowering in 4444 Patients with Coronary Heart Disease: The Scandinavian Simvastatin Survival Study (4S)", The Lancet Vol. 344, Nov. 19, 1383-1389 (1994) -C9 Shepherd, James, et al., "Prevention of Coronary Heart Disease With Pravastatin in Men With Hypercholesterolemia", The New England Journal of Medicine", Vol 333:1301-7 (1995) •

	1-2					
C10	Sacks, Frank, M., et al., "The Effect of Pravastatin on Coronary Events After Myocardial Infarction in Patients with Average Cholesterol Levels", The New England Journal of Medicine, Vol. 335:1001-9 (1996)					
C11	Heinemann, T., et al., "Mechanisms of Action of Plant Sterols on Inhibition of Cholesterol Absorption, Comparison of Sitosterol and Sitostanol", <i>European Clinical Pharmacology</i> , Vol 40: Suppl. 1:S59-S63 (1991).					
C12	Ling, W.H., et al., "Dietary Phytosterols: A Review of Metabolism, Benefits and Side Effects", <i>Life Sciences</i> , Vol. 57, No. 3:195-296 (1995)					
C13	Jones, Peter, J.H., et al., "Dietary Phytosterols as Cholesterol-Lowering Agents in Humans", Can. J. Physiol. Pharmacol. 75:217-227 (1997).					
C14	Vanhanen, Hannu, T., et al., "Serum Cholesterol, Cholesterol Precursors, and Plant Sterols in Hypercholesterolemic Subjects with Different apoE Phenotypes During Dietary Sitostanol Ester Treatment", Journal of Lipid Reseach, 34:1535-1544 (1993),					
C15	Miettinen, Tatu, A., et al., "Regulation of Cholesterol Metabolism by Dietary Plant Sterols", Current Opinion in Lipidology, 10:9-14 (1999)					
C16	Heinemann, T., et al., "Effect of Low-Dose Sitostanol on Serum Cholesterol in Patients with Hypercholesterolemia", <i>Arethrosclerosis</i> 61: 219-223 (1986)					
<b>99</b> /   C17	Vanhanen, H.T., et al., "Serum Levels, Absorption Efficiency, Faecal Elimination and Synthesis of Cholesterol During Increasing Doses of Dietary Sitostanol Esters in Hypercholesterolaemic Subjects", Clinical Science, 87:61-67 (1994)					
C18	Leaf, Alexander, et al., "Medical Progress, Cardiovascular Effects of n-3 Fatty Acids", The New England Journal of Medicine, No. 9, 318:549-557 (1988)					
C19	Mishkel, Gregory, J., et al., "Cardiovascular Effects of ω-3 Polyunsaturated Fatty Acids (Fish Oils)", Bailliere's Clinical Haematology, No. 3, 3:625-649 (1990).					
C20	Kinsella, John, E., et al., "Dietary n-3 Polyunsaturated Fatty Acids and Amelioration of Cardiovascular Disease: Possible Mechanisms <sup>1-3</sup> , Am. J. Clin. Nutr., 52:1-28 (1990).					
C21	Connor, Sonja, L., et al., "Are Fish Oils Beneficial in the Prevention and Treatment of Coronary Artery Disease?", Am. J. Clin. Nutr. 66 (Suppl.):1020S-31S (1997)					
C22	Burr, M.L., et al., "Effects of Changes in Fat, Fish, and Fibre Intakes on Death and Myocardial Reinfarction: Diet and Reinfarction Trial (Dart), <i>The Lancet</i> , 757-761 (1989).					

08/385836

		07/	385,834	P-3			
C23		von Shacky, Clemens, et al Atherosclerosis, A Randon Annals of Internal Medicin	nized, Double-Blind, Place	-3 Fatty Acids on Coronary ebo-Controlled Trial",			
C24		"Dietary Supplementation with n-3 Polyunsaturated Fatty Acids and Vitamin E after Myocardial Infarction: Results of the GISSI-Preventione Trial", <i>The Lancet</i> , 354:447-455 (1999)					
C25		Harris, William, S., "Fish ( Humans: A Critical Review	•	Lipoprotein Metabolism in rch, 30:785-807 (1989)			
C26		Carey, Martin, C., et al., "I 45:651-77 (1983).	Lipid Digestion and Absorp	ption" Ann. Rev. Physiol.			
EXAMINER	Sabiha N	· Qaz	DATE CONSIDERED 8/9	100			

EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.